Lilly/Innovent Experience Show Hurdles Remaining For Chinese PD-1 Inhibitors

 
• By Alaric DeArment
3d illustration of T cells attacking a cancer cell
ODAC voted 14-1 to recommend an additional trial for Lilly/Innovent PD-1 inhibitor sintilimab • Source: Shutterstock

More from Anticancer

More from Therapeutic Category